Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$2.29
+0.4%
$2.06
$0.98
$2.95
$26.50M0.658,306 shs20,905 shs
Vectura Group plc stock logo
VEGPF
Vectura Group
$1.77
$1.77
$1.64
$2.74
$1.07B0.372,185 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+3.64%+21.28%+14.00%+2.24%+94.87%
Vectura Group plc stock logo
VEGPF
Vectura Group
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$2.29
+0.4%
$2.06
$0.98
$2.95
$26.50M0.658,306 shs20,905 shs
Vectura Group plc stock logo
VEGPF
Vectura Group
$1.77
$1.77
$1.64
$2.74
$1.07B0.372,185 shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+3.64%+21.28%+14.00%+2.24%+94.87%
Vectura Group plc stock logo
VEGPF
Vectura Group
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.00
SellN/AN/A
Vectura Group plc stock logo
VEGPF
Vectura Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TXMD and VEGPF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/6/2026
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
DowngradeHold (C-)Sell (D-)
(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$3.02M8.70$0.05 per share47.15$2.32 per share0.98
Vectura Group plc stock logo
VEGPF
Vectura Group
$244.76M4.37$0.28 per share6.33$1.16 per share1.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$570K$0.0637.83N/AN/A5.34%0.32%0.23%8/17/2026 (Estimated)
Vectura Group plc stock logo
VEGPF
Vectura Group
$157.16M$0.266.8117.70N/AN/AN/AN/AN/A

Latest TXMD and VEGPF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 million
3/30/2026Q4 2025
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$6.1250-$0.0530+$6.0720-$0.05$19.77 million$0.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
3.11
3.11
Vectura Group plc stock logo
VEGPF
Vectura Group
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%
Vectura Group plc stock logo
VEGPF
Vectura Group
N/A

Insider Ownership

CompanyInsider Ownership
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.70%
Vectura Group plc stock logo
VEGPF
Vectura Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.38 millionOptionable
Vectura Group plc stock logo
VEGPF
Vectura Group
502604.26 millionN/ANot Optionable

Recent News About These Companies

Vectura and Hikma to develop US asthma generic
European Stocks See Mixed Session as U.K.'s FTSE Leads
VECTURA GROUP LS -,000271 (V4TA.BE)
Vectura Group PLC (V4TA.BE)
Results for 'Vectura-Fertin Pharma'
Vectura Group (OTC:VEGPF), Short Interest Report
Carlyle stays in race for Vectura
Form 8.3 - Form-8.3 - VECTURA GROUP PLC - 20210826

New MarketBeat Followers Over Time

Media Sentiment Over Time

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$2.29 +0.01 (+0.44%)
As of 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Vectura Group stock logo

Vectura Group OTCMKTS:VEGPF

$1.77 0.00 (0.00%)
As of 11/1/2021

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.